archived version — not current

This is a permanent, read-only archive of this profile's public content as it existed on 2026-09-23. It does not reflect the current, live profile. View the current profile.

Cagrilintide

Snapshot captured 2026-09-23 — Published content materially edited

Overview

Cagrilintide is an amylin analog investigated for weight management, both alone and in combinations such as CagriSema. Evidence for the single agent must be separated from evidence for the combination.

Evidence quality

WPF’s existing atlas includes systematic reviews and network meta-analyses comparing cagrilintide, CagriSema, semaglutide, and other interventions. These syntheses pose different questions and may combine heterogeneous trials; a title or indirect comparison is not proof of relative superiority.

Safety concerns

No published source-linked citation or jurisdiction-specific regulatory record has been promoted into this Directory entry. Combined-treatment results cannot be attributed to cagrilintide alone, and follow-up duration and safety outcomes need separate appraisal.

Citations as of this version

Regulatory status as of this version

United States — FDA: not_approved
European Union — EMA: not_approved

Content hash: 1de293ef8d339467f93865b7c4a3b016661a4d22ce3fe5b22498cc4aa38d5515

All archived versions